Thomas Schall is the founder of ChemoCentryx. He led the company through the successful completion of a pivotal Phase III trial for its lead drug candidate.
Thomas Schall is the Founder and Chief Executive Officer of ChemoCentryx, a biopharmaceutical company focused on developing oral drugs for inflammatory and kidney diseases. He led the company through the successful completion of a pivotal Phase III trial for its lead drug candidate avacopan in ANCA-associated vasculitis.
Full founder directory · Investor directory · Company funding database · Fundraising library